[RESEARCH BLOG] · 2026-08-28
Erasca, Inc. (ERAS) – FDA Fast‑Track Designation and $387 M BlackRock Stake Spark LOPJLB **BUY** Signal in Recovery Regime
By Pierre Brunelle · Founder & Research Lead
Erasca, Inc. closed at $19.49, up 1.78 % as of 2026‑08‑27. The LOPJLB proprietary scanner has issued a BUY directional signal with a perfect Score 5 while the broader market regime is flagged as RECOVERY. The combination of fresh regulatory momentum, a sizable institutional position, and a balanced quantitative archetype has moved the stock into the spotlight for investors tracking high‑growth biotech names.
Recent News Flow
-
BlackRock Inc. Takes $387.54 Million Position in Erasca, Inc. $ERAS — disclosed on 2026‑08‑26. The filing shows a $387.54 million equity purchase, lifting BlackRock’s stake to a material level and signaling confidence from one of the world’s largest asset managers in Erasca’s pipeline potential.
-
Erasca Granted FDA Fast Track Designation for Pan‑RAS Molecular Glue ERAS‑0015 in Patients with Metastatic Pancreatic Adenocarcinoma — announced on 2026‑08‑24. The U.S. FDA granted Fast‑Track status to Erasca’s pan‑RAS molecular glue candidate ERAS‑0015, expediting review for a high‑unmet‑need indication.
-
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty — filed on 2026‑08‑26. The shareholder‑investigation alert probes possible fiduciary‑duty breaches by Erasca’s board, adding a governance‑risk dimension to the stock’s profile.
-
Alger Mid Cap 40 ETF Q2 2026 Portfolio Review — released on 2026‑08‑25. The ETF’s Q2 2026 portfolio lists Erasca among its biotech holdings, reflecting a thematic tilt toward mid‑cap growth companies with strong oncology pipelines.
-
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB — reported on 2026‑08‑18. The European fund’s acquisition adds another global institutional voice to the growing list of investors tracking Erasca’s clinical progress.
Fundamentals and Valuation
Erasca remains a clinical‑stage biopharmaceutical firm focused on RAS/MAPK‑driven malignancies. The balance sheet and earnings metrics illustrate the typical risk‑reward profile of a biotech still in development.
- Trailing P/E (TTM): ‑20.52
- EV/EBITDA: ‑23.81
- Price‑to‑Book (P/B): 16.77
- DCF‑derived implied value: 19,679.7 % of current market cap
Profitability metrics are negative: gross, operating, and net margins are 0 %. Return ratios are distressed (ROIC ‑48.26 %, ROE ‑80.43 %, ROA ‑66.02 %). The Debt‑to‑Equity ratio stands at 12.36, indicating modest leverage for a biotech that funds cash‑burn primarily through equity.
Analyst consensus targets the stock at $22.50, a 15.4 % upside from the current close, with a Buy recommendation.
| Metric | Value |
|---|---|
| P/E (TTM) | ‑20.52 |
| EV/EBITDA | ‑23.81 |
| P/B | 16.77 |
| Analyst Target ($) | 22.50 |
| Debt‑to‑Equity | 12.36 |
Historical Earnings Context
EPS has improved from ‑$0.85 in 2020 to ‑$0.44 in 2025. Free cash flow, while still negative, moved from ‑$71.4 M (2020) to ‑$95.6 M (2025) as R&D outlays increased. The PE ratio has narrowed from ‑20.40 (2020) to ‑8.47 (2025), indicating that losses are shrinking relative to share price, though the company remains pre‑revenue.
ETF Ownership
Seven ETFs hold Erasca, providing a diversified institutional base that can amplify price moves during rebalancing. Top holdings are:
The concentration in biotech‑focused ETFs suggests short‑term volatility around quarterly rebalancing, while the broader exposure offers steady demand and liquidity.
LOPJLB Signal Overview
The LOPJLB engine has generated a BUY directional signal for ERAS, assigning a Score of 5—the highest confidence tier. The signal sits within a RECOVERY market regime (18‑day stretch of positive equity momentum). Composite PERF rating is 50.50 and FUND quality score is 18.40, placing Erasca in the upper‑mid tier for both price performance and fundamentals despite negative earnings.
Quantitative scores: Value 8.00, Growth 45.00, GARP 6.00, Quality 18.40, yielding a Balanced archetype. This reflects strong growth expectations (Fast‑Track designation, pipeline progress) combined with a moderate quality profile (manageable debt, buy‑rated consensus).
For the full overlay of technical and quantitative signals, see the interactive chart above the article, and review the methodology at the LOPJLB methodology page.
What to Watch Next
- Regulatory Milestones – Upcoming read‑outs for ERAS‑0015 and Phase I/II data for ERAS‑007 could trigger partnership or licensing activity.
- Shareholder Investigation Outcome – Findings from the Bernstein Liebhard probe may affect board composition and proxy voting dynamics.
- Institutional Flow – BlackRock’s sizable stake and continued European accumulation suggest expanding institutional ownership, potentially providing price support.
- ETF Rebalancing – Quarterly fund rebalancing could create short‑term price swings; monitoring fund flow reports will help gauge impact.
Further Research & Disclaimers
For a deeper dive into Erasca’s financials, recent filings, and the full suite of LOPJLB analytics, visit the dedicated stock page at lopjlb.com/stock/ERAS. Quarterly earnings details (when available) can be accessed at lopjlb.com/stock/ERAS/earnings.md. To screen for similar biotech opportunities, explore the LOPJLB screener.
The information provided herein is for research purposes only and does not constitute investment advice. All investors should conduct their own due diligence and consider their risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.